Alex Lovejoy's Biography

Alex Lovejoy, Principal Scientist, Roche Sequencing Solutions

Alex Lovejoy earned his PhD in Biochemistry from Stanford University where he focused on developing new NGS-based technologies in Pat Brown’s lab. As a postdoctoral scholar in the Oncology Department at Stanford, he worked on the CAPP-Seq technology for ctDNA NGS, a technology which was acquired by Roche. For the past 3 years, he has been working in the Oncology Assay Development team at Roche Sequencing Solutions, improving upon the technology and designing and developing the next generation of oncology assays.

The Unique Challenges and Opportunities of Circulating Tumor DNA

Friday, 29 March 2019 at 09:00

Add to Calendar ▼2019-03-29 09:00:002019-03-29 10:00:00Europe/LondonThe Unique Challenges and Opportunities of Circulating Tumor DNACirculating Biomarkers World Congress 2019 in Coronado Island, CaliforniaCoronado Island, CaliforniaSELECTBIOenquiries@selectbiosciences.com

Despite the promise of circulating tumor DNA (ctDNA) as a minimally invasive biomarker, the detection and quantification of small amounts of ctDNA in a plasma sample is a difficult problem. Limited input molecules, background noise, and cost of sequencing are all challenges that hinder the implementation of assays for ctDNA detection. This talk will describe these difficulties in detail, as well as the development of the Roche AVENIO ctDNA Analysis Kits (Research Use Only), which have been specifically designed to overcome these challenges.

Add to Calendar ▼2019-03-27 00:00:002019-03-29 00:00:00Europe/LondonCirculating Biomarkers World Congress 2019Circulating Biomarkers World Congress 2019 in Coronado Island, CaliforniaCoronado Island, CaliforniaSELECTBIOenquiries@selectbiosciences.com

Corporate Sponsors